| | By Darren Incorvaia The Trump administration is halting research funding to Princeton University and reviewing more than $9 billion in federal grants and contracts to Harvard University, the latest escalation of the government’s cuts to scientific research institutions. |
|
|
|
By Fraiser Kansteiner In resigning as director of the FDA’s Center for Biologics Evaluation and Research, Peter Marks, M.D., Ph.D., blasted the promotion of vaccine disinformation under new HHS Secretary Robert F. Kennedy Jr. |
By Eric Sagonowsky Peter Marks, M.D., Ph.D., a target for RFK Jr. and allies, last week turned in his resignation as director of the FDA's Center for Biologics Evaluation and Research. Before that, FDA commissioner Marty Makary signed off on his ouster, according to Politico. |
By Darren Incorvaia While coming back down from 2023’s dizzying high, Merck & Co. still managed to hang on to the top spot of our annual research and development budgets list. |
By Gabrielle Masson At least 63 biopharma layoff rounds were conducted in the first quarter of this year, with cell and gene biotechs accounting for nearly a third of those rounds. The cuts were accompanied by eight biotech closures as the sector faces deep uncertainty tied to recent geopolitical changes. |
By Gabrielle Masson Vence Bonham Jr., the highest ranking official at the National Human Genome Research Institute, has been put on administrative leave. |
By Gabrielle Masson The FDA’s Chief Medical Officer Hilary Marston, M.D., is leaving her position at the agency amid huge cuts to staff across the FDA. |
By Fraiser Kansteiner On Wednesday, President Donald Trump unveiled another wave of tariffs but did not mention pharmaceutical-specific tariffs. Plus, pharmaceuticals are included in a list of products exempt from the new round of reciprocal duties. |
By Fraiser Kansteiner While the FDA’s inspection figures for drug manufacturing facilities have yet to fully recover from the COVID-19 pandemic, sweeping staff cuts from the Department of Health and Human Services (HHS) could exacerbate the problem even further, CBS News reports. |
By Conor Hale The ruling was issued for a pair of lawsuits brought against the FDA by the American Clinical Laboratory Association and the Association for Molecular Pathology. |
By Andrea Park Nearly a year after a jury decided that Johnson & Johnson should be fined just over $150 million in a lawsuit alleging that the company engaged in misleading marketing tactics for two of its HIV meds, a judge has upped the penalty more than tenfold. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we dive into our special report ranking the top pharma R&D budgets for 2024. |
|
|---|
|
|
|
Copay programs are designed to make treatments more affordable, but too often, patients don’t know they exist or how to use them. That means financial assistance goes unused, medications go unfilled, and patients face unnecessary barriers to starting and staying on treatment. Join us to learn how to move beyond outdated, manual copay distribution methods. Register now.
|
|
| ResearchWe interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperRead about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperDiscover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
| WhitepaperDevelop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| |
|
